Cervical Cancer, Uterine Cervical Cancer, Uterine Cervical Neoplasms
Conditions
Brief summary
Cervical cancer is one of the major health problems for chinese women. Besides surgery and radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many studies. However, not all patients respond well to neoadjuvant chemotherapy. Knowing the therapeutic effect of the neoadjuvant chemotherapy before receiving it can not only reduce the economic burden, but also more importantly save time to take more suitable treatments. This study is undertaken to build specific molecular signatures to predict the effects of neoadjuvant chemotherapy.
Interventions
None listed
Sponsors
Zhejiang University
Wuhan Central Hospital
Huazhong University of Science and Technology
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Inclusion criteria
* Untreated cervical cancer with FIGO stage Ib-IIb * Measurable lesions * Possible to radical hysterectomy * Age: 18 and older * Karnofsky Performance Status≥ 70. * WBC \> 3,000/mm³, Hb \> 9.0g/dl, Platelet \> 100,000 /mm³, SGOT/SGPT \< 60 IU/L, T-Bil \< 1.5 mg/dL, Cr \< 1.2 mg/dL, PaO2 \> 80 torr, normal ECG * Written informed consent
Exclusion criteria
* Previous history of cancer * Patients with previous treatment * Patients without information of clinical risk factors * Patients who have active infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The clinical response to neoadjuvant chemotherapy | 1 to 3 months | clinical response（tumor size） |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The pathological response to neoadjuvant chemotherapy | 1 to 3 months | pathological response（\<3 mm or not） |
Countries
China
Contacts
Primary ContactMa Ding, M.D.
Outcome results
None listed